Emotional surgery for tubo-ovarian abscess identified extended-spectrum beta-lactamase-producing *Escherichia coli*: the first case presentation revealing causative bacteria

Teppei Tokumaru¹*, Yasuo Shima¹, Takehiro Okabayashi¹, Kazutoshi Hayashi², Yorito Yamamoto², Kazuhide Ozaki¹ and Jun Iwata³

Abstract

We report herein a 41-year-old female with a tubo-ovarian abscess (TOA), which microbial cultures showed to contain extended-spectrum beta-lactamase (ESBL)-producing *E. coli*, a causative agent of community-acquired infection. The patient initially presented with acute abdominal pain and back pain. Pelvic computed tomography and transvaginal ultrasonography revealed multiple cystic lesions in the bilateral ovaries that suggested TOA. An emergency laparotomy was therefore performed due to the potential for life-threatening septic shock from the TOA-associated pelvic inflammatory disease. Microbial cultures of postoperative fluid discharge from the placed intra-abdominal catheter, vaginal secretions, urine, blood, and feces detected ESBL-producing *E. coli*. In summary, we successfully performed emergency surgery for life-threatening septic TOA caused by ESBL-producing *E. coli* infection.

Keywords: Emergency surgery; Tubo-ovarian abscess; Extended-spectrum beta-lactamase; Surgery

Background

A tubo-ovarian abscess (TOA) can develop in reproductive age women with pelvic inflammatory disease (PID). The cause of TOA is mostly ascending infection through the uterus (mainly sexually transmitted diseases) due to *Neisseria gonorrhoeae*, *Chlamydia*, *Escherichia coli* (*E. coli*), and/or endogenous bacteria of the vagina and cervix [1, 2]. The management of TOA is a fundamentally conservative treatment with systemic broad-spectrum antibiotics. However, a TOA can have serious and potentially life-threatening consequences when there is a risk of abscess rupture. In such cases, antibiotic therapy is not sufficient for treating the TOA, and surgical drainage must be performed [3–6].

In this case report of a patient with TOA, surgery was indicated after the initial diagnosis due to the immediate threat of clinically dangerous septic shock. Although the abscesses were not ruptured, infections to the vagina, uterus, and bilateral ovaries by extended-spectrum beta-lactamase (ESBL)-producing *E. coli* had the potential to induce septic shock and disseminated intravascular coagulation, both of which can be life-threatening conditions. ESBL-producing bacteria infect individuals with impaired immunity, have resistance to many antibiotics, and can cause nosocomial infection [7–12]. To our knowledge, this is the first reported case of a patient with TOA caused by ESBL-producing *E. coli* and treated with emergency surgery.

Case presentation

A 41-year-old woman presenting with acute abdominal and back pain was admitted into a neighboring hospital. She was initially diagnosed with a urinary tract infection and received systemic antibiotic therapy for 2 days. She complained of worsening abdominal pain and high fever, suggesting PID due to bacterial infection into the bilateral ovaries, and was subsequently referred to our hospital. She was previously healthy with no history of...
heavy alcohol consumption, smoking, diabetes mellitus, or overseas travel.

Physical examination revealed a body temperature of 40 degrees, mild abdominal pain, and markedly anemic conjunctiva. Her abdomen was soft, but showed mild tenderness and rebound pain. Hematological and biochemical testing showed a red blood cell count of $280 \times 10^4/\mu L$ (normal range, $370–490 \times 10^4/\mu L$), hematocrit of 22.5% (normal range, 34–49%), hemoglobin (Hb) level of 7.3 g/dL (normal range, 11.2–15.7 g/dL), white blood cell count of 16,500/\mu L, platelet count of 18,000/\mu L, C-reactive protein level of 18.0 mg/dL, aspartate transaminase (AST) of 146 IU/L (normal range, 8–38 IU/L), alanine transaminase (ALT) of 79 IU/L (normal range, 4–44 IU/L), alkaline phosphatase (ALP) of 563 IU/L (normal range, 115–359 IU/L), lactate dehydrogenase (LD) of 899 IU/L (normal range, 106–211 IU/L); total protein concentration of 4.6 g/dL (normal range, 6.7–8.3 g/dL), albumin levels of 2.0 g/dL (normal range, 3.8–5.3 g/dL), cholinesterase concentration of 104 IU/L (normal range, 229–521 IU/L), creatinine concentration of 3.1 mg/dL (normal range, 0.4–0.8 mg/dL), prothrombin time of 44.1% (normal range, 77.0–104.0%), activated partial thromboplastin time, 47.7 s (normal range, 20.0 to 40.0 s), fibrin/fibrinogen degradation products at 239.4 ug/mL (normal range, 0.0–10.0 ug/mL), D-dimer levels of 75.1 ug/mL (normal range, 0.0–1.0 ug/mL), antithrombin 3 activity of 53% (normal range, 81–123%), base excesses of $-13.0 \text{ mmol/L}$ (normal range, $-3.0–3.0 \text{ mmol/L}$), and lactate concentration of 12.9 mmol/L (normal range, 0.5–2.0 mmol/L). Other laboratory tests, including tumor markers (carcinoembryonic antigen, carbohydrate 19–9, and carbohydrate antigen 125) and viral status for hepatitis B status and C status, were normal. Abdominal computed tomography (CT) revealed thick-walled multilocular cystic lesions in the bilateral ovaries, and no ascites in the pelvis (Fig. 1). TOA was strongly suspected, and the patient underwent transvaginal ultrasonography, which demonstrated an 11.1 × 7.9 cm left ovarian cystic mass with low echogenicity, and a 6.3 × 4.4 cm right ovarian mass with a similar echo-texture (Fig. 2). For further definitive diagnosis, ultrasound-guided puncture was conducted in the cystic mass and revealed a purulent content. Together, the clinical presentation and imaging findings provided a diagnosis of TOA. An emergency laparotomy was performed based on the clinical diagnosis of septic shock and already completed DIC due to the TOA.

The gross examination during surgery showed inflammation around the bilateral ovaries that was so marked that it prevented identification of individual organs. The bilateral ovaries and uterus were firm to palpate; however, the vagina in the pelvic cavity was relatively soft on palpitation. The inflammatory lesions including the ovaries and the uterus containing a uterine fibroid were resected to control oozing hemorrhage from the pelvic cavity because the patient showed evidence of DIC. During this procedure, the cystic component was partially damaged and discharged a small amount of purulent fluid, which subsequent cultures showed to contain ESBL-producing E.coli. Resected specimens of the bilateral ovaries showed marked swelling and thick-walled multilocular cystic lesions with intraluminal abscesses (Fig. 3). Microscopic examination of the resected specimen revealed
infiltration of foamy cells and neutrophils into the abscess cavity (Fig. 4). No cell types showed atypical mitotic images or pleomorphisms.

Postoperative microbial cultures of the fluid discharge from the placed intra-abdominal catheter, vaginal secretions, urine, blood, and feces detected ESBL-producing \textit{E. coli}. The patient suffered further abscess formation due to infection of the postoperative hematoma in the pelvic cavity, and underwent a repeat laparotomy with abdominal drainage for diffuse peritonitis 12 days after the initial surgery. She subsequently suffered intra-abdominal septic complications, and underwent ultrasound-guided percutaneous drainage on the 27th postoperative day. After the drainage, she made a favorable recovery and was discharged from our hospital 72 days after the first emergency surgery.

**Discussion**

TOA is most frequently induced by ascending infection through the uterus due to \textit{Neisseria}, \textit{gonorrhoeae}, \textit{Chlamydia}, \textit{E. coli}, or indigenous bacteria of the vagina and cervix, and it usually follows PID [1, 2]. Herein, we present the first reported case of a patient with TOA caused by ESBL-producing \textit{E. coli}.

ESBL-producing bacteria is well known as one of the multiple-antibiotic-resistant bacterium identified by German Knothe in 1983 [13]. Our case had no comorbidity, including diabetes mellitus, respiratory disease, ischemic heart disease, immune-deficiency disease, and had never been hospitalized following birth. Thus, we considered this case to be a community-acquired infection. Most infections due to ESBL-producing bacteria remain hospital-acquired and are even more common among long-term hospitalized and immunocompromised patients [8]. Recently, however, the incidence of community-acquired infection by ESBL-producing bacteria has gradually increased in Western countries, although it remains rare in Japan, and the increasing numbers reported have been attributed to advances in diagnostic techniques and equipments [12, 14, 15]. In the recent years, it has been reported that the incidence of colonization induced by community-acquired ESBL-producing bacteria from urine and/or feces has been increased, even with patients with no comorbidities in Japan as the West. Therefore, the current study suggested that physicians should pay attention to the community-acquired infection of ESBL-producing bacteria which might have been increased in the future [14, 16, 17].

Treatment of TOA is important to avoid complications such as life-threatening abscess rupture and sepsis, and to preserve fertility, so early detection and treatment of TOA can prevent such adverse outcomes. However, the peculiar clinical signs of TOA are absent, such as lower abdominal tenderness, abnormal vaginal or cervical discharge, fever, abnormal vaginal bleeding, dyspareunia, cervical motion tenderness, and adnexal tenderness [18, 19]. Furthermore, it was also very difficult to detect clinically TOA according to laboratory investigations like following-findings, presence of excess leucocytes, and/or C-reactive protein [19]. The differential diagnosis for TOA includes a

![Fig. 3 Resected specimen of ovary, showing marked swelling of the bilateral ovaries with intraluminal abscess. Pathological examination revealed the presence of ectopic endometriosis around the ovary (white arrowheads)](image-url)
wide array, such as reproductive system disease, gastrointestinal inflammation, urinary tract infection. Therefore the diagnosis of TOA based on clinical criteria alone at the early stage is difficult and inaccurate [18, 19]. In the present case, the diagnosis of potential TOA was suggested strongly by subsequent transvaginal ultrasound. Interestingly, this patient with insufficiency of intravenous antibiotics treatment ran a fatal course due to subsequent septic complication for TOA in only two days. In general, ruptured TOA can rapidly become critical for the patient, whereas unruptured TOA commonly progresses slowly [19, 20]. A rapid onset of endotoxin shock and DIC is commonly inferred with Gram-negative E. coli, especially in this case with detection of the multiple-antibiotic-resistant ESBL-producing bacteria, which produces endotoxin and generally enter the bloodstream and peritoneal pelvic cavity, causing high fever and acute lower abdominal pain.

Therapeutically, when conservative management with antibiotics is ineffective, surgical management is strongly recommended for TOA [4, 7]. As surgical management, surgical drainage, salpingo-oophorectomy, and abdominal hysterectomy in combination with antibiotics is generally performed in women with TOA [21–23], with the aim of being minimally invasive and as conservative as possible [24–27]. In our case, because the TOA could have developed under septic conditions and thus rapidly induce the critical condition of DIC, we immediately proceeded with surgical treatment by salpingooophorectomy and hysterectomy.

In conclusion, we successfully performed emergency surgery for life-threatening septic TOA caused by ESBL-producing E. coli, which was not controlled with conservative antibiotic treatment. To ensure the best management of such cases, reporting of cases with similar pathological and bacteriological findings is warranted.

Conclusions
Aggressive surgery is a valid choice for treating TOA in specific life-threatening situations.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests

Authors’ contributions
This work was supported by the Kochi organization for medical reformation and renewal grants. TT wrote the manuscript and researched data. YO, TO, KH, YY, KO, and JI researched data. YS and TO reviewed/edit the manuscript. KH, YY KO, and JI contributed to discussion and reviewed/edit the manuscript. YS researched data and contributed to discussion. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by the Kochi organization for medical reformation and renewal grants.

Author details
1Department of Gastroenterological Surgery, Kochi Health Sciences Center, 2125-1 Ike, Kochi-City, Kochi 781-8555, Japan. 2Department of Obstetrics and Gynecology, Kochi Health Sciences Center, 2125-1 Ike, Kochi-City, Kochi 781-8555, Japan. 3Department of Diagnostic Pathology at Kochi Health Science Center, 2125-1 Ike, Kochi-City, Kochi 781-8555, Japan.

Received: 15 June 2015 Accepted: 10 August 2015 Published online: 15 August 2015

References
1. Granberg S, Gjelland K, Ekerhovd E. The management of pelvic abscess. Best Pract Res Clin Obstet Gynaecol. 2009;23(5):667–78.
2. Yavuzcan A, Çağlar M, Dibbar S, Kumru S, Avcioglu F, Ustün Y. Identification of Clostridium septicum in a tubo-ovarian abscess: a rare case and review of the literature. Vojnosanit Pregl. 2014;71(9):884–8.
3. Garbin O, Verdon R, Faconnier A. Treatment of the tubo-ovarian abscesses. J Gynecol Obstet Biol Reprod. 2012;41(8):875–85.
4. Roberts W, Dockery JL. Operative and conservative treatment of tubo-ovarian abscess due to pelvic inflammatory disease. South Med J. 1984;77(7):860–3.
5. Chappell CA, Wiesenfeld HC. Pathogenesis, diagnosis, and management of severe pelvic inflammatory disease and tuboovarian abscess. Clin Obstet Gynecol. 2012;55(4):893–903.

6. Nakayama K, Ishikawa M, Katagiri H, Katagiri A, Ishibashi T, Iida K, et al. Surgical treatment outcomes of serious chronic tubo-ovarian abscess: a single-center series of 20 cases. Clin Exp Obstet Gynecol. 2013;40(3):377–80.

7. Ben-Ami R, Rodríguez-Baño J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis. 2009;49(5):682–90.

8. Shah AA, Hasan F, Ahmed S, Hameed A, Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect. 2009;73(4):345–54.

9. Shah AA, Hasan F, Ahmed S, Hameed A. Extended-spectrum beta-lactamases (ESβLs): characterization, epidemiology and detection. Crit Rev Microbiol. 2004;30(1):25–32.

10. Cantón R, Novais A, Valverde A, Machado E, Peixe L, Baquero F, et al. Prevalence and spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Europe. Clin Microbiol Infect. 2008;14 Suppl 1:144–53.

11. Bush K. Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect. 2008;14 Suppl 1:134–43.

12. Hirokata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, et al. Regional variation in the prevalence of extended-spectrum beta-lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002). Diagn Microbiol Infect Dis. 2005;52(4):323–9.

13. Krothe H, Shah P, Kromer V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, ceftoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection. 1983;11(6):315–7.

14. Doi Y, Park YS, Rivera JJ, Adams-Haduch JM, Hingwe A, Sordillo EM, et al. Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis. 2013;56(5):641.

15. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–86.

16. Kawamura I, Ohmagari N, Tsukahara M, Kudo T, Kuri H. Surveillance of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a comprehensive cancer center in Japan, 2009-2013. Am J Infect Control. 2015;43(2):185–7.

17. Chong Y, Shimoda S, Yakushiji H, Ito Y, Miyamoto T, Kamimura T, et al. Community spread of extended-spectrum β-lactamase-producing Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis: a long-term study in Japan. J Med Microbiol. 2013;62(Pt 7):1038–43.

18. Terao M, Koga K, Fujimoto A, Wada-Hiraike O, Osuga Y, Yano T, et al. Factors that predict poor clinical course among patients hospitalized with pelvic inflammatory disease. J Obstet Gynecol Res. 2014;40(2):495–500.

19. Landers DV, Sweet RL. Tubo-ovarian abscess: contemporary approach to management. Rev Infect Dis. 1983;5(5):876.

20. Wiesenfeld HC, Sweet RL. Progress in the management of tuboovarian abscesses. Clin Obstet Gynecol. 1993;36(2):433.

21. Pedowitz P, Bloomfield RD. Ruptured adnexal abscess (tuboovarian) with generalized peritonitis. Am J Obstet Gynecol. 1964;88:721.

22. Vermeeren J, Te Linde RW. Intraabdominal rupture of pelvic abscesses. Am J Obstet Gynecol. 1954;68:1-402.

23. Krivak TC, Cooksey C, Propst AM. Tubo-ovarian abscess: diagnosis, medical and surgical management. Compr Ther. 2004;30(2):93–100.

24. Riesen M, Breitkopf D, Waud K. Tubo-ovarian abscess: management options for women who desire fertility. Obstet Gynecol Surv. 2009;64(10):681–93.

25. Mizushima T, Yoshida H, Ohi Y, Ishikawa M, Hirahara F. Evaluating the risk factors for developing resistance to parenteral therapy for tubo-ovarian abscess: a case-control study. J Obstet Gynecol Res. 2013;39(5):1019–23.

26. Buchwitz O, Malik E, Kressin P, Meyhoefer-Malki A, Diedrich K. Laparoscopic management of tubo-ovarian abscesses: retrospective analysis of 60 cases. Surg Endosc. 2000;14(10):948–50.

27. Geißen K, Granberg S, Kiserud T, Wenzel-Larsen T, Ekerhoff E. Pregnancies following ultrasound-guided drainage of tubo-ovarian abscesses. Fertil Steril. 2012;98(1):36–40.